Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Re-Vana Therapeutics Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct art units. The prosecution involves the distinct examiner GREENE, IVAN A, who is the busiest examiner and is responsible for 1 pending office action. This distribution indicates that the 2 pending actions are being handled by separate examiners.
The Biotechnology & Pharmaceuticals focus remains consistent across the portfolio, even as the matters are handled by separate examiners. Having 2 pending office actions in 2 distinct art units suggests that the company is pursuing multiple technical avenues within its field. Practitioners should be prepared to manage different examiner preferences while maintaining a unified strategy. The presence of GREENE, IVAN A as the busiest examiner with 1 pending office action indicates an even distribution of the current workload. This decentralized approach can help the company navigate the USPTO more effectively by engaging with multiple divisions. The legal team should monitor both art units for any diverging trends that could impact the prosecution of the 2 pending matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GREENE, IVAN A | 1 | 18.7% | +6.4% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000937 | BIODEGRADABLE COMPOSITIONS AND IMPLANTS | FAY, ZOHREH ALEMZADEH | 58d overdue |
| 18223944 | OCULAR COMPOSITIONS | GREENE, IVAN A | 44d overdue |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18223944 | OCULAR COMPOSITIONS | GREENE, IVAN A | 1619 | §103§112Other | Final Rejection | 44d overdue | Pending | Jul 19, 2023 |
| 18000937 | BIODEGRADABLE COMPOSITIONS AND IMPLANTS | FAY, ZOHREH ALEMZADEH | 1617 | §103§112 | Final Rejection | 58d overdue | Pending | Dec 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial